Back to Search
Start Over
Eterna inks option and license agreement with Lineage Cell Therapeutics to develop iPSC lines for multiple neurology indications
- Source :
- PharmaBiz. February 23, 2023
- Publication Year :
- 2023
-
Abstract
- Eterna Therapeutics Inc., a preclinical-stage biotechnology company announced that it has entered into an exclusive option and license agreement (the 'Agreement') with Lineage Cell Therapeutics, Inc. (Lineage) for the development [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.738271649